Relapsing-remitting


Also found in: Acronyms.

Relapsing-remitting

A pattern of symptoms of multiple sclerosis in which symptomatic attacks occur that last 24 hours or more, followed by complete or almost complete improvement.
Mentioned in: Multiple Sclerosis
References in periodicals archive ?
The European Medicines Agency also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis, or RRMS, in the European Union.
Progressive MS is divided into primary progressive MS (approximately 15% of all patients) and secondary progressive MS that follows a period of relapsing-remitting disease course [1].
GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis, or RRMS.
Today, twelve drugs have been approved for the treatment of relapsing-remitting multiple sclerosis; for the progressive types, on the other hand, only a few therapy approaches exist.
M2 EQUITYBITES-December 4, 2017-Merck passes Health Canada's approval for MAVENCLAD (Cladribine Tablets) to treat relapsing-remitting multiple sclerosis
M2 PHARMA-December 4, 2017-Merck passes Health Canada's approval for MAVENCLAD (Cladribine Tablets) to treat relapsing-remitting multiple sclerosis
(NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS).
Adults living with relapsing-remitting MS may be helped by new treatment, Tecfidera, as the National Institute for Health and Care Excellence (Nice) has issued approval guidance for its use.
SAN DIEGO -- Full results of the second phase III trial of dimethyl fumarate in patients with relapsing-remitting multiple sclerosis show that the investigational drug significantly reduced annualized relapse rates and MRI lesions over the course of 2 years.
Its effect in people with relapsing-remitting MS (RRMS) compared with the earlier experience in those with progressing disease seems to delineate clearly the difference between the initial systemic, inflammatory disease and the subsequent progressive, degenerative disease confined within the central nervous system.
Summary: TEHRAN (FNA)- A new study for comparing the efficacy of 250 micro/g or 500 micro/g interferon beta-1b with Glatiramer acetate for treating relapsing-remitting multiple sclerosis showed that both doses had similar clinical effects to Glatiramer acetate.